Parnax Lab Q4 FY26: Sales Jump 42%, But the Operating Margin Fell Off a Cliff to 7%

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Parnax Lab closed FY26 with consolidated sales of ₹248.54 Cr, up from ₹187.74 Cr the year before — a 32% jump that would headline most annual entries. The fourth quarter carried the growth: ₹69.63 Cr of revenue against ₹49.04 Cr a year earlier, a 42% rise. Then the operating line does something the top line doesn’t prepare you for. Q4 operating profit came in at ₹4.88 Cr, down from ₹6.63 Cr a year earlier, and the operating margin dropped to 7.01% — the lowest quarterly reading in the three-year window on the sheet, against 13.52% in the same quarter last year and 10.88% the quarter before.

Full-year PAT was ₹11.78 Cr, barely above FY25’s ₹11.52 Cr despite the ₹61 Cr of extra revenue. The company holds a WHO-approved contract-manufacturing facility at Silvassa, ₹82.78 Cr of borrowings, and a long-term credit rating parked at BWR D under “issuer not cooperating.” A 42% revenue quarter that produced a shrinking operating profit is the tension the rest of this entry unpacks.

2 — Introduction

Parnax Lab Ltd was incorporated in 1985 and manufactures and exports pharmaceutical formulations. It sits inside the Naxpar Group and describes itself as WHO-approved and EHS-compliant, running contract manufacturing of liquid orals, capsules, ointments, external powders and tablets out of Silvassa.

There is a structural quirk worth naming early, because it explains the numbers. Almost the entire business lives in the subsidiary, not the listed parent. For the year ended March 2026, the standalone parent booked revenue from operations of ₹6.63 Cr. The consolidated group booked ₹248.54 Cr. The subsidiary, Naxpar Pharma Private Limited — 99.80% owned per the FY23 annual report — carried total revenue of ₹243.27 Cr and net profit of ₹10.91 Cr. The listed entity you buy a share of is, in standalone terms, mostly a holding vehicle; the operating story is one layer down.

On the corporate side, the board approved the FY26 audited results on 28 May 2026 and reappointed Yogesh K. Varia as a non-executive independent director for a second five-year term. The auditors issued an unmodified opinion. That is the recent record — no more, no less.

3 — Business Model: WTF Do They Even Do?

They make things in bottles and tubes for companies whose names you actually recognise. Parnax is a contract manufacturer of oral formulations — cough expectorants, antacids, anti-histamines, multivitamins, enzymes, paediatric and geriatric formulations — plus cosmetics, herbal balms and nutraceutical syrups. The listed client roster reads like a pharma trade-show badge wall: Himalaya, L’Oréal, Sun Pharma, Cipla, Dabur, Wockhardt. Parnax does the manufacturing; the brands do the selling.

Capacity is real and specific: liquid orals of roughly 30–60 KL per day, ointments and creams of 10–20 tons per day, powders of 1–2 tons per day. Exports go to Nigeria, Kazakhstan, Kenya and Mauritius, with stated plans toward South East Asia, CIS and LatAm.

The economics of contract manufacturing are the economics on display here. You take the volume, you take the volatility of input costs, and you hand the pricing power to whoever owns the brand on the label. That is the model working exactly as designed — and it is also why a 42% sales quarter can arrive with a 7% operating margin. When the customer owns the brand, the manufacturer owns the cost line. Does a client list full of blue-chip names help, if the margin still lands where a job-worker’s does?

4 — Financials Overview

Figures are consolidated, in ₹ crore.

The quarter is a split screen: revenue accelerating, everything below the operating line going the other way. Q4 expenses